Amgen Opens Nomination Process For LabCentral Residency
Aine Hanly, vice president of
"We know there are many more life-science visionaries with great technology and terrific science, and we're thrilled that
Johannes Fruehauf, M.D., Ph.D. "These contests help get the word out, ensuring that there continues to be a broad pool of applicants with the highest potential. Further, since
The 2016 Golden Ticket nomination process opened on
Since the collaboration launched in 2014,
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
About LabCentral (www.labcentral.org; twitter @labcentral)
A 28,000 square-foot facility in the heart of the